Uscom Ltd
ASX:UCM
Intrinsic Value
Uscom Ltd. engages in the development, design, manufacture, and marketing of non-invasive cardiovascular and pulmonary medical devices. [ Read More ]
The intrinsic value of one UCM stock under the Base Case scenario is 0.038 AUD. Compared to the current market price of 0.031 AUD, Uscom Ltd is Undervalued by 19%.
Valuation Backtest
Uscom Ltd
Run backtest to discover the historical profit from buying and selling UCM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Uscom Ltd
Current Assets | 4.7m |
Cash & Short-Term Investments | 3.2m |
Receivables | 735.9k |
Other Current Assets | 754.5k |
Non-Current Assets | 1.4m |
Long-Term Investments | 83.5k |
PP&E | 809k |
Intangibles | 460.1k |
Other Non-Current Assets | -10 |
Current Liabilities | 3m |
Accounts Payable | 532k |
Accrued Liabilities | 189k |
Short-Term Debt | 2m |
Other Current Liabilities | 263.8k |
Non-Current Liabilities | 884.2k |
Long-Term Debt | 779.1k |
Other Non-Current Liabilities | 105.1k |
Earnings Waterfall
Uscom Ltd
Revenue
|
3.4m
AUD
|
Cost of Revenue
|
-535.9k
AUD
|
Gross Profit
|
2.9m
AUD
|
Operating Expenses
|
-5.2m
AUD
|
Operating Income
|
-2.4m
AUD
|
Other Expenses
|
282.3k
AUD
|
Net Income
|
-2.1m
AUD
|
Free Cash Flow Analysis
Uscom Ltd
UCM Profitability Score
Profitability Due Diligence
Uscom Ltd's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Uscom Ltd's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
UCM Solvency Score
Solvency Due Diligence
Uscom Ltd's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Uscom Ltd's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
UCM Price Targets Summary
Uscom Ltd
Shareholder Return
UCM Price
Uscom Ltd
Average Annual Return | -18.92% |
Standard Deviation of Annual Returns | 41.88% |
Max Drawdown | -95% |
Market Capitalization | 7.6m AUD |
Shares Outstanding | 244 588 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Uscom Ltd. engages in the development, design, manufacture, and marketing of non-invasive cardiovascular and pulmonary medical devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2003-12-10. The firm manages a network of distribution partners across the world for the sale of its equipment to hospitals and other medical care locations. Its geographic segments include Singapore, Australia, China, South East Asia, Europe and the United States. The firm has approximately three practice suites of devices in the field of cardiac, vascular and pulmonary monitoring, including the USCOM 1A, which is an hemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment, USCOM BP+, which is a supra systolic oscillometric Central Blood Pressure monitor that measures blood pressure and blood pressure waveforms only previously available using cardiac catheterization, and the Uscom SpiroSonic spirometers, which is a digital pulmonary testing device.
Contact
IPO
Employees
Officers
The intrinsic value of one UCM stock under the Base Case scenario is 0.038 AUD.
Compared to the current market price of 0.031 AUD, Uscom Ltd is Undervalued by 19%.